Drugs / Fuzheng Huayu
Fuzheng Huayu
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials | ||||||
| Phase 3 | NCT02916290 | Jan 2016 → Dec 2018 | primary biliary cholangitis | Xijing Hospital of Digestive Diseases | Unknown | No outcome recorded |
| Phase 3 | NCT02916641 | Jan 2016 → Dec 2018 | primary biliary cholangitis | Xijing Hospital of Digestive Diseases | Unknown | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT02945956 | Apr 2018 → Jun 2020 | portal hypertension | ShuGuang Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02945982 | Apr 2018 → Jun 2020 | portal hypertension | ShuGuang Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02241616 | Sep 2014 → Jun 2019 | cirrhosis of liver | ShuGuang Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02241590 | Sep 2014 → Jun 2019 | cirrhosis of liver | ShuGuang Hospital | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00854087 Comparator | Aug 2010 → Apr 2013 | chronic hepatitis C virus infection | Tarek Hassanein | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fuzhenghuayu | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02916290 ↗ |
| Known as | Fuzheng Huayu Tablet | “Chinese medicines (CMs), particularly Fuzheng Huayu Tablet (, FZHY), have an antifibrotic effect in patients with CHB.” PMID 32572776 ↗ Jun 2020 |
| Known as | FZHY | “Chinese medicines (CMs), particularly Fuzheng Huayu Tablet (, FZHY), have an antifibrotic effect in patients with CHB.” PMID 32572776 ↗ Jun 2020 |
| Modality | Traditional medicine (herbal / TCM) | “anti-fibrotic herbal product such as FZHY” PMID 32572776 ↗ Jun 2020 |
| Route | Oral | “4 FZHY tablets (1.6 g) three times a day” PMID 32642592 ↗ Jun 2020 |